TARGETS FOR IMMUNOTHERAPY IN ACUTE LEUKEMIA

Aims & Scope:

The promise of immunotherapy in the treatment of human malignancy has been recognized scientifically for over one hundred years with, until very recently, limited tangible impact on the clinical care of most cancer patients. The past twenty four months have seen dramatic advances in translating this dream into a reality however with successful clinical trials of immune active agents both alone and in combination; with particularly notable successes seen in the leukemias. Historically, acute leukemia was the first cancer for which immunotherapy (in the form of allogenic hematopoietic stem cell transplantation) was sufficiently successful to be adopted as a clinical standard of care. The aim of this issue is to review the recent evidence that immunotherapy represents the most promising current treatment approach currently in development for the acute leukemias and highlight specific areas of human immunobiology that may be targetable by clinical intervention.

Key words:

Immunotherapy, Antigens, Cellular Therapy, Acute Myeloid Leukemia, Acute Lymphoid Leukemia

Subtopics:

Antigen targets in acute lymphoblastic leukemia
Antigen targets in acute myeloid leukemia
Immunomodulatory drugs I: IMiDs
Immunomodulatory drugs II: Immune Checkpoint Agents
Natural Killer Cell Immunobiology in Acute Leukemia
Targets for Chimeric Antigen Receptors
Adoptive immunotherapy with ex vivo expanded T cells
Antibody based therapeutics for acute leukemia.
Advances in immune modulation in allogeneic stem cell transplantation
Haploidentical microtransplantation and donor lymphocyte infusion

Schedule:

Manuscript submission deadline: October 2014
Peer Review Due: November 2014
Revision Due: December 2014
Notification of acceptance by the Guest Editor: January 2015
Final manuscripts due: January 2015